Regorafenib improves survival of colorectal cancer patients

Drug improves survival of colorectal cancer patients, trial results show – Regorafenib – an investigational drug – slowed the progression of tumors and lengthened the lives of patients with metastatic colorectal cancer. This is the first novel agent in eight years to show improvement in overall survival of colon cancer patients who have run out of treatment options.

Health Newstrack